Heterogeneous distribution of
EGFR mutation
Pyrosequencing
Real Time PCR
S768I
intratumoral heterogeneity
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
08
2022
accepted:
11
05
2023
medline:
30
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
We herein report the case of a patient with advanced lung adenocarcinoma who presented a heterogeneous distribution of A 74-year-old Moroccan male former smoker was diagnosed with advanced lung adenocarcinoma, harboring S768I exon 20 substitution mutation confirmed by Real Time PCR and Pyrosequencing, but not detected by direct sequencing despite 70% of tumor cells. The present report describes a case of minor histologic intratumoral heterogeneity with heterogeneous distribution of Both sensitivity and specificity of molecular methods can provide evidence of intratumoral heterogeneity, which may explain the mismatch between the validation of oncology biomarkers and predicting therapeutic response to targeted therapy.
Sections du résumé
Background
UNASSIGNED
We herein report the case of a patient with advanced lung adenocarcinoma who presented a heterogeneous distribution of
Case report
UNASSIGNED
A 74-year-old Moroccan male former smoker was diagnosed with advanced lung adenocarcinoma, harboring S768I exon 20 substitution mutation confirmed by Real Time PCR and Pyrosequencing, but not detected by direct sequencing despite 70% of tumor cells. The present report describes a case of minor histologic intratumoral heterogeneity with heterogeneous distribution of
Conclusion
UNASSIGNED
Both sensitivity and specificity of molecular methods can provide evidence of intratumoral heterogeneity, which may explain the mismatch between the validation of oncology biomarkers and predicting therapeutic response to targeted therapy.
Identifiants
pubmed: 37251359
doi: 10.1016/j.rmcr.2023.101871
pii: S2213-0071(23)00066-7
pmc: PMC10212754
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101871Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
All authors declare that there is no conflict of interest.
Références
Jpn J Clin Oncol. 2010 Nov;40(11):1105-9
pubmed: 20522446
J Clin Oncol. 2011 Aug 1;29(22):2972-7
pubmed: 21730270
J Exp Clin Cancer Res. 2011 May 16;30:57
pubmed: 21575212
J Transl Med. 2014 May 16;12:131
pubmed: 24885034
Cancer Sci. 2008 May;99(5):929-35
pubmed: 18325048
Target Oncol. 2017 Feb;12(1):81-88
pubmed: 27538584
Nature. 2005 Sep 15;437(7057):376-80
pubmed: 16056220
J Thorac Oncol. 2008 May;3(5):527-9
pubmed: 18449007
Science. 2014 Oct 10;346(6206):251-6
pubmed: 25301630
Oncotarget. 2016 Jul 19;7(29):45237-45248
pubmed: 27304188
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
BMC Cancer. 2019 Apr 23;19(1):369
pubmed: 31014278
Int J Cancer. 2008 Dec 1;123(11):2480-6
pubmed: 18785203
Asia Pac J Clin Oncol. 2019 Jun;15(3):166-171
pubmed: 30311393
Virchows Arch. 2012 Apr;460(4):407-14
pubmed: 22419261
Oncol Lett. 2016 May;11(5):3546-3550
pubmed: 27123149
PLoS One. 2015 Sep 30;10(9):e0139264
pubmed: 26422230
Future Oncol. 2019 Feb;15(6):637-652
pubmed: 30404555
Diagn Mol Pathol. 2013 Dec;22(4):196-203
pubmed: 24193003
Cancer Chemother Pharmacol. 2012 Feb;69(2):289-99
pubmed: 22130585
Oncotarget. 2015 May 20;6(14):12783-95
pubmed: 25904052